Evidence map›Paper›PMID 25685551›Full record

Trial reportInternational journal of surgical oncology2015

Evaluating the feasibility of performing window of opportunity trials in breast cancer.

Angel Arnaout, Susan Robertson, Iryna Kuchuk, Demetrios Simos, Gregory R Pond, Christina L Addison, Mehrzad Namazi, Mark Clemons

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Angel ArnaoutDivision of Surgical Oncology, Department of Surgery, Ottawa Hospital, Ottawa, ON, Canada ; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0002-1546-3548
Susan RobertsonDivision of Anatomical Pathology, Ottawa Hospital, Ottawa, ON, Canada.ORCID 0000-0003-0479-6651
Iryna KuchukDivision of Medical Oncology, Department of Medicine, Ottawa Hospital and Ottawa Hospital Cancer Center, Ottawa, ON, Canada.
Demetrios SimosDivision of Medical Oncology, Department of Medicine, Ottawa Hospital and Ottawa Hospital Cancer Center, Ottawa, ON, Canada.ORCID 0000-0003-4592-3346
Gregory R PondDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Christina L AddisonCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Mehrzad NamaziDivision of Surgical Oncology, Department of Surgery, Ottawa Hospital, Ottawa, ON, Canada.
Mark ClemonsCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada ; Division of Medical Oncology, Department of Medicine, Ottawa Hospital and Ottawa Hospital Cancer Center, Ottawa, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe waiting period to surgery represents a valuable "window of opportunity" to evaluate novel therapeutic strategies. Interventional studies performed during this period require significant multidisciplinary collaboration to overcome logistical hurdles. We undertook a one-year prospective window of opportunity study to assess feasibility.

methodsEligible newly diagnosed postmenopausal, estrogen receptor positive breast cancer patients awaiting primary surgery received anastrozole daily until surgery. Feasibility was assessed by (a) the proportion of patients who consented and (b) completed the study. Comparison of pre- and poststudy Ki67 labelling index and cleaved caspase 3 scores (CC3) was performed.

results22/131 (16.8%) patients were confirmed eligible and 20/22 (91%) patients completed the study. 19/20 (95%) patients agreed to undergo optional additional tissue biopsies. The mean duration of anastrozole use was 24.7 (15-44) days. There were a statistically significant decline in mean Ki67 indices of 48.8% (p < 0.001) and a trend towards significance in the decline of CC3 (p = 0.17) when comparing pre- with posttreatment values.

conclusionwindow of opportunity trials in breast cancer are a feasible way of assessing the biologic efficacy of different therapies in the presurgical setting. The majority of eligible women were willing to participate including undergoing additional tissue biopsies.

Indexed as

AgedAged, 80 and overAnastrozoleAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastChemotherapy, AdjuvantDrug Administration ScheduleFeasibility StudiesFemaleHumansMastectomyMiddle AgedNeoadjuvant TherapyNitrilesAnastrozoleAntineoplastic Agents, HormonalBiomarkers, TumorNitrilesTriazoles

Identifiers

PMID25685551
PMCPMC4320871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.